England & Company is pleased to announce that NIRx Medical Technologies, LLC (“NIRx”), a pioneer in functional Near-Infrared Spectroscopy (fNIRS) neuroimaging systems and the market leader in this rapidly growing market, has been acquired by Gilde Healthcare Partners BV (“Gilde”), a Netherlands-based healthcare investor specializing medtech, digital health, and therapeutics. NIRx’s systems enable non-invasive, radiation-free, real-time brain imaging for neuroscience research in both lab and natural settings. As part of a strategic combination, Gilde has also acquired Artinis Medical Systems B.V. (“Artinis”), a complementary fNIRS company. This combination creates a global leader in fNIRS and is the foundation for building a market leader in innovative neuroimaging and neuroscience research tools more broadly.
NIRx Group CEO, Richard Barbour, said: “The England team added significant value in negotiating this transaction and bringing it to a successful close. They also went above and beyond with additional financial advisory assistance.” Dr. Patrick Britz, CEO of NIRx GmbH added “It was really a pleasure working with the England team. Their support, attention to detail, diligence, and advice on the deal were instrumental in achieving this amazing result.”
NIRx provides cutting-edge solutions to researchers in human neuroscience to enhance the understanding of the human mind, health, and disease. Through its innovative and comfortable-wearing head gear, NIRx offers a host of integrated technology solutions that support a wide range of investigative aims – from exploring early language acquisition in infants to motor movements in the natural environment to BCI applications or new understandings involving coordinated actions between sensory systems, NIRS imaging solutions from NIRx constitute a comprehensive resource that meet the most demanding applications.
As established leaders in fNIRS, NIRx and Artinis will merge as a newly formed platform within Gilde for neuroimaging and corresponding research tools, all while driving innovation across multiple modalities. The goal of this new platform is to enhance the adoption of fNIRS in applied neuroscience by setting industry standards and making the technology more accessible to academic and institutional researchers globally.
“By bringing both companies together, we are creating a platform that will lead innovation and makes brain imaging tools more accessible to researchers globally,” said Boyd Rutten, Investment Director, Gilde Healthcare.